We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Investment Ideas feature highlights: Twitter, Facebook and Netflix
Read MoreHide Full Article
For Immediate Release
Chicago, IL – July 30, 2018 – Today, Zacks Investment Ideas feature highlights Features: Twitter , Facebook and Netflix (NFLX - Free Report) .
Twitter Meets on Earnings, but Stock Gets Punished
Shares in Twitter traded down almost 20% on Friday after the company reported quarterly earnings that were in line with projections and beat the consensus estimate for revenues.
Investors focused instead on an unexpected decline in monthly average users at the social-media giant.
Prior to the report, Twitter had rallied 78% in 2018 and in what is becoming a recurring theme during this earnings season, the market appears to have expected perfection and was quick to punish the shares on even a slight suggestion that growth may be slowing.
Net earnings of $0.17/share exactly matched the Zacks Consensus Estimate and represent growth of 112% over the same quarter in 2017. Revenues of $711 billion exceeded the consensus of $700B.
In a predominantly upbeat letter to investors, Twitter highlighted growth in daily average users of 11% year-over-year but a slight decline of monthly average users from 336 million in Q1 to 335 million in Q2.
Even though Twitter has reported 15 straight quarters of results at or above analyst expectations, it’s fairly high trailing P/E ratio of 81X left precious little margin for error.
The decline was not totally unexpected and is largely the result of a company initiative intended to purge “fake” accounts.
Though the deletion of accounts that are suspected of sharing misleading or inappropriate content was expected to reduce follower counts by up to 6%, it’s reasonable to expect that Twitter’s ability to monetize advertising views should be largely unaffected.
Just as we saw with Facebook and Netflix, it seems that investors in popular tech stocks have their finger on the “sell” button at the first sign of any slowdown in growth. Twitter’s actions to strengthen its platform and user base could easily be seen as a positive factor in the company’s long-term prospects, but instead a tiny miss in one single metric sent the shares down 20%.
The investor letter details at length the exact criteria Twitter uses to decide about accounts to delete and the specific effect those actions can be expected to have on DAU and MAU. Twitter literally couldn’t be more transparent about what they’re doing and why.
Other than the single number than riled the markets, Twitter is poised to continue growing users, revenues and profits and management is unafraid to make temporarily painful decisions in order to ensure the long term health of the company.
It’s easy to see today’s selloff as an outstanding opportunity to initiate or add to a position in a company that promises to be a social-media powerhouse for years to come.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Investment Ideas feature highlights: Twitter, Facebook and Netflix
For Immediate Release
Chicago, IL – July 30, 2018 – Today, Zacks Investment Ideas feature highlights Features: Twitter , Facebook and Netflix (NFLX - Free Report) .
Twitter Meets on Earnings, but Stock Gets Punished
Shares in Twitter traded down almost 20% on Friday after the company reported quarterly earnings that were in line with projections and beat the consensus estimate for revenues.
Investors focused instead on an unexpected decline in monthly average users at the social-media giant.
Prior to the report, Twitter had rallied 78% in 2018 and in what is becoming a recurring theme during this earnings season, the market appears to have expected perfection and was quick to punish the shares on even a slight suggestion that growth may be slowing.
Net earnings of $0.17/share exactly matched the Zacks Consensus Estimate and represent growth of 112% over the same quarter in 2017. Revenues of $711 billion exceeded the consensus of $700B.
In a predominantly upbeat letter to investors, Twitter highlighted growth in daily average users of 11% year-over-year but a slight decline of monthly average users from 336 million in Q1 to 335 million in Q2.
Even though Twitter has reported 15 straight quarters of results at or above analyst expectations, it’s fairly high trailing P/E ratio of 81X left precious little margin for error.
The decline was not totally unexpected and is largely the result of a company initiative intended to purge “fake” accounts.
Though the deletion of accounts that are suspected of sharing misleading or inappropriate content was expected to reduce follower counts by up to 6%, it’s reasonable to expect that Twitter’s ability to monetize advertising views should be largely unaffected.
Just as we saw with Facebook and Netflix, it seems that investors in popular tech stocks have their finger on the “sell” button at the first sign of any slowdown in growth. Twitter’s actions to strengthen its platform and user base could easily be seen as a positive factor in the company’s long-term prospects, but instead a tiny miss in one single metric sent the shares down 20%.
The investor letter details at length the exact criteria Twitter uses to decide about accounts to delete and the specific effect those actions can be expected to have on DAU and MAU. Twitter literally couldn’t be more transparent about what they’re doing and why.
Other than the single number than riled the markets, Twitter is poised to continue growing users, revenues and profits and management is unafraid to make temporarily painful decisions in order to ensure the long term health of the company.
It’s easy to see today’s selloff as an outstanding opportunity to initiate or add to a position in a company that promises to be a social-media powerhouse for years to come.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions. New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Follow us on Twitter: http://twitter.com/ZacksResearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.